0001792941 2026-04-01 2026-06-30 0001792941 srt:MaximumMember us-gaap:SubsequentEventMember 2026-07-17 2026-07-17 0001792941 srt:MinimumMember us-gaap:SubsequentEventMember 2026-07-17 2026-07-17 0001792941 us-gaap:SubsequentEventMember 2026-07-17 0001792941 2025-10-01 2026-06-30 0001792941 srt:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2026-05-18 2026-05-18 0001792941 srt:ChiefFinancialOfficerMember 2026-05-18 2026-05-18 0001792941 gnvr:CFOServicesAgreementMember 2026-06-30 0001792941 gnvr:CFOServicesAgreementMember 2026-05-18 0001792941 srt:MinimumMember gnvr:CFOServicesAgreementMember 2026-05-18 0001792941 srt:MaximumMember gnvr:CFOServicesAgreementMember 2026-05-18 0001792941 2026-05-18 2026-05-18 0001792941 srt:ChiefExecutiveOfficerMember gnvr:EmploymentAgreementMember 2024-12-20 0001792941 srt:ChiefExecutiveOfficerMember gnvr:OriginalAgreementMember 2024-01-17 0001792941 srt:ChiefExecutiveOfficerMember 2024-01-17 0001792941 srt:ChiefExecutiveOfficerMember 2024-01-17 2024-01-17 0001792941 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2024-01-17 2024-01-17 0001792941 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-01-17 2024-01-17 0001792941 gnvr:DrClaytonYatesMember gnvr:FederalAgenciesMember 2024-01-17 0001792941 gnvr:DrClaytonYatesMember gnvr:CommercialSaleMember 2024-01-17 0001792941 gnvr:DrClaytonYatesMember gnvr:RegulatoryMember 2024-01-17 0001792941 gnvr:DrClaytonYatesMember gnvr:BiologicalFungicideMember 2024-01-17 0001792941 gnvr:DrClaytonYatesMember 2024-01-17 2024-01-17 0001792941 gnvr:DrClaytonYatesMember 2024-01-17 0001792941 gnvr:DrClaytonYatesMember 2025-09-30 0001792941 gnvr:DrClaytonYatesMember 2026-06-30 0001792941 gnvr:DrJesseJaynesMember gnvr:FederalAgenciesMember 2024-01-17 0001792941 gnvr:DrJesseJaynesMember gnvr:CommercialSaleMember 2024-01-17 0001792941 gnvr:DrJesseJaynesMember gnvr:EnvironmentalProtectionAgencyMember 2024-01-17 0001792941 gnvr:DrJesseJaynesMember gnvr:BiologicalFungicideMember 2024-01-17 0001792941 gnvr:DrJesseJaynesMember 2024-01-17 2024-01-17 0001792941 gnvr:DrJesseJaynesMember 2024-01-17 0001792941 gnvr:DrJesseJaynesMember 2025-09-30 0001792941 gnvr:DrJesseJaynesMember 2026-06-30 0001792941 gnvr:MrKimboughMember 2025-10-22 0001792941 2024-10-01 2025-06-30 0001792941 2025-04-01 2025-06-30 0001792941 srt:ChiefExecutiveOfficerMember 2025-09-30 0001792941 us-gaap:RelatedPartyMember 2026-06-30 0001792941 srt:ChiefExecutiveOfficerMember us-gaap:RelatedPartyMember 2025-09-30 0001792941 srt:ChiefExecutiveOfficerMember us-gaap:RelatedPartyMember 2026-06-30 0001792941 srt:ChiefExecutiveOfficerMember gnvr:ScientificAdvisorsMember 2025-09-30 0001792941 srt:ChiefExecutiveOfficerMember gnvr:ScientificAdvisorsMember 2026-06-30 0001792941 srt:ChiefExecutiveOfficerMember 2026-06-30 0001792941 srt:ChiefExecutiveOfficerMember us-gaap:RelatedPartyMember 2024-10-01 2025-06-30 0001792941 srt:ChiefExecutiveOfficerMember us-gaap:RelatedPartyMember 2025-10-01 2026-06-30 0001792941 srt:ChiefFinancialOfficerMember us-gaap:RelatedPartyMember 2026-06-30 0001792941 gnvr:OtherGeneralAndAdministrativeExpensesMember 2025-10-01 2026-06-30 0001792941 gnvr:OtherGeneralAndAdministrativeExpensesMember 2026-04-01 2026-06-30 0001792941 gnvr:ResearchAndDevelopmentExpensesMember 2025-10-01 2026-06-30 0001792941 gnvr:ResearchAndDevelopmentExpensesMember 2026-04-01 2026-06-30 0001792941 gnvr:CompensationAndRelatedBenefitsMember 2025-10-01 2026-06-30 0001792941 gnvr:CompensationAndRelatedBenefitsMember 2026-04-01 2026-06-30 0001792941 2026-06-30 0001792941 gnvr:AccruedCompensationDirectorJaynesMember 2026-06-30 0001792941 gnvr:AccruedCompensationDirectorYatesMember 2026-06-30 0001792941 srt:ChiefExecutiveOfficerMember 2026-06-30 0001792941 srt:BoardOfDirectorsChairmanMember 2026-06-30 0001792941 srt:BoardOfDirectorsChairmanMember 2025-10-01 2026-06-30 0001792941 srt:ChiefFinancialOfficerMember 2026-06-30 0001792941 srt:ChiefFinancialOfficerMember us-gaap:RelatedPartyMember 2025-09-30 0001792941 gnvr:ActingChiefFinancialOfficerMember 2026-06-30 0001792941 gnvr:ActingChiefFinancialOfficerMember 2026-05-21 0001792941 gnvr:ScientificAdvisorsMember gnvr:ConsultingAgreementsMember 2025-09-30 0001792941 gnvr:ScientificAdvisorsMember gnvr:ConsultingAgreementsMember 2026-06-30 0001792941 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2025-01-01 0001792941 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2025-01-01 0001792941 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-01-01 0001792941 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2025-01-01 2025-01-01 0001792941 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-01-01 0001792941 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-01-01 0001792941 gnvr:WarantsMember 2026-01-01 2026-06-30 0001792941 gnvr:WarantsMember 2025-10-01 2025-12-31 0001792941 gnvr:WarantsMember 2025-12-31 0001792941 gnvr:WarantsMember 2025-09-30 2025-09-30 0001792941 gnvr:WarantsMember 2025-09-30 0001792941 us-gaap:CommonStockMember 2024-10-01 2025-06-30 0001792941 2026-03-11 0001792941 srt:ChiefExecutiveOfficerMember gnvr:CommonStockIssuedServicesMember 2026-03-11 2026-03-11 0001792941 us-gaap:CommonStockMember 2026-03-11 2026-03-11 0001792941 us-gaap:ShareSettlementMember gnvr:CommonStockIssuedServicesMember 2024-10-01 2025-06-30 0001792941 us-gaap:CommonStockMember 2025-10-01 2026-06-30 0001792941 gnvr:BrentLilienthalMember 2024-10-01 2025-06-30 0001792941 gnvr:BrentLilienthalMember 2025-06-30 0001792941 us-gaap:CommonStockMember 2025-10-01 2026-06-30 0001792941 gnvr:BrentLilienthalMember us-gaap:InvestorMember us-gaap:CommonStockMember 2024-09-30 0001792941 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2024-10-01 2025-06-30 0001792941 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001792941 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2025-10-01 2026-06-30 0001792941 gnvr:EmployeesMember 2024-10-01 2025-06-30 0001792941 gnvr:ScientificAdvisorMember 2024-10-01 2025-06-30 0001792941 srt:ChiefExecutiveOfficerMember 2025-06-30 0001792941 srt:ChiefExecutiveOfficerMember 2024-10-01 2025-06-30 0001792941 gnvr:CommonStockIssuedServicesMember 2025-10-01 2026-06-30 0001792941 srt:MinimumMember us-gaap:CommonStockMember 2025-10-01 2026-06-30 0001792941 srt:MaximumMember us-gaap:CommonStockMember 2025-10-01 2026-06-30 0001792941 us-gaap:WarrantMember 2024-10-01 2025-06-30 0001792941 us-gaap:WarrantMember 2025-06-30 0001792941 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-10-01 2025-06-30 0001792941 us-gaap:WarrantMember 2025-10-01 2026-06-30 0001792941 us-gaap:InvestorMember 2024-10-01 2025-06-30 0001792941 us-gaap:InvestorMember 2025-06-30 0001792941 gnvr:PrefundedWarrantMember us-gaap:CommonStockMember 2026-06-30 0001792941 gnvr:PrefundedWarrantMember us-gaap:CommonStockMember 2025-10-01 2026-06-30 0001792941 gnvr:PJAdvisoryGroupMember 2025-10-01 2026-06-30 0001792941 us-gaap:CommonStockMember 2026-06-30 0001792941 us-gaap:SeriesCPreferredStockMember 2025-10-01 2026-06-30 0001792941 us-gaap:SeriesCPreferredStockMember 2026-04-01 2026-06-30 0001792941 2026-05-05 0001792941 2026-05-05 2026-05-05 0001792941 us-gaap:SeriesCPreferredStockMember 2026-05-05 2026-05-05 0001792941 us-gaap:SeriesCPreferredStockMember 2026-05-05 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001792941 gnvr:PJAdvisoryGroupMember us-gaap:CommonStockMember 2025-10-01 2026-06-30 0001792941 srt:ChiefExecutiveOfficerMember 2023-09-28 2023-09-28 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-19 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001792941 us-gaap:SeriesAPreferredStockMember 2022-08-10 2022-08-10 0001792941 us-gaap:SeriesAPreferredStockMember 2022-08-10 0001792941 2025-09-30 0001792941 2026-03-31 0001792941 srt:MaximumMember 2025-10-01 2026-06-30 0001792941 srt:MinimumMember 2025-10-01 2026-06-30 0001792941 gnvr:OTCMember 2026-06-30 0001792941 gnvr:SeriesCMember 2025-10-01 2026-06-30 0001792941 gnvr:VWAPMember 2025-10-01 2026-06-30 0001792941 gnvr:VWAPMember 2026-04-01 2026-06-30 0001792941 2026-05-04 2026-05-04 0001792941 gnvr:SeriesCMember 2026-05-04 2026-05-04 0001792941 gnvr:VWAPMember 2026-05-05 2026-05-05 0001792941 us-gaap:SeriesCPreferredStockMember 2026-05-04 0001792941 2026-04-16 2026-04-16 0001792941 gnvr:AdvisoryAgreementMember 2026-04-16 2026-04-16 0001792941 us-gaap:MeasurementInputExpectedDividendRateMember 2026-06-30 0001792941 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-06-30 0001792941 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2026-06-30 0001792941 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2026-06-30 0001792941 us-gaap:MeasurementInputSharePriceMember 2026-06-30 0001792941 us-gaap:MeasurementInputPriceVolatilityMember 2026-06-30 0001792941 us-gaap:FairValueInputsLevel3Member 2025-10-01 2026-06-30 0001792941 us-gaap:FairValueInputsLevel3Member 2026-06-30 0001792941 us-gaap:ConvertibleNotesPayableMember 2026-06-30 0001792941 gnvr:PaycheckProtectionProgramMember gnvr:SmallBusinessAdministrationMember 2020-04-08 2020-04-09 0001792941 gnvr:PaycheckProtectionProgramMember gnvr:SmallBusinessAdministrationMember 2020-04-09 0001792941 us-gaap:ConvertibleNotesPayableMember 2025-10-31 0001792941 us-gaap:ConvertibleNotesPayableMember 2025-10-01 2025-10-31 0001792941 us-gaap:ConvertibleNotesPayableMember 2025-10-01 2026-06-30 0001792941 us-gaap:ConvertibleNotesPayableMember gnvr:PreFundedWarrantsMember 2024-09-09 0001792941 us-gaap:ConvertibleNotesPayableMember 2024-09-09 0001792941 gnvr:ConvertiblePromissoryNoteMember 2024-09-09 0001792941 us-gaap:ConvertibleNotesPayableMember 2025-09-30 0001792941 us-gaap:ConvertibleNotesPayableMember 2024-10-01 2025-06-30 0001792941 us-gaap:ConvertibleNotesPayableMember 2025-04-01 2025-06-30 0001792941 us-gaap:MeasurementInputSharePriceMember us-gaap:BlackScholesMertonModelMember 2026-06-30 0001792941 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:BlackScholesMertonModelMember 2026-06-30 0001792941 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:BlackScholesMertonModelMember 2026-06-30 0001792941 us-gaap:MeasurementInputExpectedTermMember us-gaap:BlackScholesMertonModelMember 2026-06-30 0001792941 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:BlackScholesMertonModelMember 2026-06-30 0001792941 us-gaap:BlackScholesMertonModelMember 2025-10-01 2026-06-30 0001792941 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember us-gaap:BlackScholesMertonModelMember 2026-06-30 0001792941 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember us-gaap:BlackScholesMertonModelMember 2026-06-30 0001792941 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:BlackScholesMertonModelMember 2026-06-30 0001792941 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:BlackScholesMertonModelMember 2026-06-30 0001792941 us-gaap:WarrantMember 2026-06-30 0001792941 gnvr:LetterAgreementMember 2026-06-30 0001792941 gnvr:LetterAgreementMember 2025-10-01 2026-06-30 0001792941 gnvr:LetterAgreementMember gnvr:FourTrancheMember 2026-06-17 2026-06-17 0001792941 gnvr:LetterAgreementMember gnvr:ThirdTranchesMember 2026-06-17 2026-06-17 0001792941 srt:MaximumMember gnvr:LetterAgreementMember gnvr:FourTrancheMember 2026-06-17 0001792941 srt:MinimumMember gnvr:LetterAgreementMember gnvr:FourTrancheMember 2026-06-17 0001792941 us-gaap:ConvertibleNotesPayableMember gnvr:SecuritiesPurchaseAgreementMember 2026-04-16 2026-04-16 0001792941 gnvr:SecuritiesPurchaseAgreementMember 2026-04-16 0001792941 us-gaap:WarrantMember 2026-04-16 2026-04-16 0001792941 2025-06-30 0001792941 gnvr:ConvertibleNotesMember 2024-10-01 2025-06-30 0001792941 gnvr:ConvertibleNotesMember 2025-04-01 2025-06-30 0001792941 gnvr:SeriesCPreferredStockConvertibleMember 2025-10-01 2026-06-30 0001792941 gnvr:SeriesCPreferredStockConvertibleMember 2026-04-01 2026-06-30 0001792941 gnvr:SeriesBPreferredStockConvertibleMember 2024-10-01 2025-06-30 0001792941 gnvr:SeriesBPreferredStockConvertibleMember 2025-10-01 2026-06-30 0001792941 gnvr:SeriesBPreferredStockConvertibleMember 2025-04-01 2025-06-30 0001792941 gnvr:SeriesBPreferredStockConvertibleMember 2026-04-01 2026-06-30 0001792941 gnvr:SeriesAPreferredStockConvertibleMember 2024-10-01 2025-06-30 0001792941 gnvr:SeriesAPreferredStockConvertibleMember 2025-10-01 2026-06-30 0001792941 gnvr:SeriesAPreferredStockConvertibleMember 2025-04-01 2025-06-30 0001792941 gnvr:SeriesAPreferredStockConvertibleMember 2026-04-01 2026-06-30 0001792941 gnvr:WarrantsToPurchaseCommonStockMember 2024-10-01 2025-06-30 0001792941 gnvr:WarrantsToPurchaseCommonStockMember 2025-10-01 2026-06-30 0001792941 gnvr:WarrantsToPurchaseCommonStockMember 2025-04-01 2025-06-30 0001792941 gnvr:WarrantsToPurchaseCommonStockMember 2026-04-01 2026-06-30 0001792941 2022-05-01 2022-05-27 0001792941 gnvr:LegacyGenvorMember 2022-05-27 0001792941 2022-05-27 0001792941 2024-09-30 0001792941 us-gaap:RetainedEarningsMember 2026-06-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2026-06-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001792941 gnvr:CommonStockToBeIssuedMember 2026-06-30 0001792941 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001792941 gnvr:CommonStockToBeIssuedMember 2026-04-01 2026-06-30 0001792941 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001792941 us-gaap:RetainedEarningsMember 2026-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2026-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001792941 us-gaap:CommonStockMember 2026-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001792941 2026-01-01 2026-03-31 0001792941 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001792941 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001792941 2025-12-31 0001792941 us-gaap:RetainedEarningsMember 2025-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2025-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001792941 us-gaap:CommonStockMember 2025-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001792941 2025-10-01 2025-12-31 0001792941 us-gaap:RetainedEarningsMember 2025-10-01 2025-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2025-10-01 2025-12-31 0001792941 us-gaap:CommonStockMember 2025-10-01 2025-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-10-01 2025-12-31 0001792941 us-gaap:RetainedEarningsMember 2025-09-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2025-09-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001792941 us-gaap:CommonStockMember 2025-09-30 0001792941 us-gaap:RetainedEarningsMember 2025-06-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2025-06-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001792941 us-gaap:CommonStockMember 2025-06-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001792941 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001792941 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001792941 2025-03-31 0001792941 us-gaap:RetainedEarningsMember 2025-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2025-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001792941 us-gaap:CommonStockMember 2025-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001792941 2025-01-01 2025-03-31 0001792941 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001792941 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001792941 2024-12-31 0001792941 us-gaap:RetainedEarningsMember 2024-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2024-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001792941 us-gaap:CommonStockMember 2024-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001792941 2024-10-01 2024-12-31 0001792941 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001792941 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001792941 us-gaap:RetainedEarningsMember 2024-09-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2024-09-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001792941 us-gaap:CommonStockMember 2024-09-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001792941 us-gaap:SeriesCPreferredStockMember 2025-09-30 0001792941 us-gaap:SeriesCPreferredStockMember 2026-06-30 0001792941 us-gaap:SeriesBPreferredStockMember 2025-09-30 0001792941 us-gaap:SeriesBPreferredStockMember 2026-06-30 0001792941 us-gaap:SeriesAPreferredStockMember 2025-09-30 0001792941 us-gaap:SeriesAPreferredStockMember 2026-06-30 0001792941 us-gaap:RelatedPartyMember 2025-09-30 0001792941 2026-08-14 0001792941 gnvr:ConvertibleNotesMember 2026-04-01 2026-06-30 0001792941 gnvr:ConvertibleNotesMember 2025-10-01 2026-06-30 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-10-01 2025-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2025-10-01 2025-12-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0001792941 gnvr:CommonStockToBeIssuedMember 2025-09-30 0001792941 gnvr:CommonStockToBeIssuedMember 2025-12-31 0001792941 gnvr:CommonStockToBeIssuedMember 2026-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-10-01 2024-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-10-01 2024-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2024-10-01 2024-12-31 0001792941 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001792941 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001792941 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001792941 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001792941 gnvr:SeriesCPreferredStockConvertibleMember 2025-04-01 2025-06-30 0001792941 gnvr:SeriesCPreferredStockConvertibleMember 2024-10-01 2025-06-30 0001792941 us-gaap:FairValueInputsLevel1Member 2026-06-30 0001792941 us-gaap:FairValueInputsLevel1Member 2025-09-30 0001792941 us-gaap:FairValueInputsLevel2Member 2026-06-30 0001792941 us-gaap:FairValueInputsLevel2Member 2025-09-30 0001792941 us-gaap:FairValueInputsLevel3Member 2025-09-30 0001792941 gnvr:WarantsMember 2026-06-30 shares pure iso4217:USD iso4217:USD shares

P5D P10D P5Y

false --09-30 Q3 0001792941 10-Q true 2026-06-30 2026 false 000-56589 GENVOR INCORPORATED NV 83-2054746 1550 W Horizon Ridge Pkwy Ste R #3040 Henderson NV 89012 (715) 903-6473 Yes Yes Non-accelerated Filer true true true false 36410120

196522

37231

65721

8591

262243

45822

50000

312243

45822

317189

20000

18059

5834

2211

92431 54815

116916

366899

484392 781392 1646487

84137

48750

2814195

1358204

212364

3026559

1358204

0.001

20000000

2500000

1910536

2060536

1408024

1558024

1911

2061

0.001

300000000

36410120

30175763

36410

30175

0.001 0.001 265666 0 266

27302718

25148688

502512

300000

-29755621

-26193306

-2714316

-1312382

312243

45822

205977

271816

320352

390052

15281

42073

3758

481851

80356

728811

100436

1516403 184824 2042749 5283418

261501

40547

317175

73349

2481013

577543

3451160

5851013

-2481013

-577543

-3451160

-5851013

61703

16138

91046

42902

8902 -6357 8902 187000 187000

13752

-75455

179764

-111155

153000

-2556468

-397779

-3562315

-5698013

-2556468

-397779

-3562315

-5698013

-0.07

-0.01

-0.1

-0.23

36083168

27471752

34654540

24331752

2060536

2061

20029608

20030

19168044

-502512

-300000

-20604265

-1714130

4875000

4875

4870125

4875000

-5001251

2060536

2061

24904608

24905

24038169

-502512

-300000

-25605516

-1840381

250000

250

62250

62500

-298983

2060536

2061

25154608

25155

24100419

-502512

-300000

-25904499

-2076864

1720000 1720 428280 430000

250000

250

62250

62500

1300000 1300 323700 325000 120000 120 29880 30000 120000 120 29880 30000

310000

310

-310

500000

500

-397779

2060536

2061

29474608

29475

24974099

-502512

-300000

-26302278

-1596643

2060536

2061

30175763

30175

25148688

-502512

-300000

-26193306

-1312382

-150000 -150 1500000 1500 -1350 520000 520 259480 260000

1440000

1440

-1440

225000

225

109775

110000

505000 505 125745 126250 124000 124 185876 186000 250000 250 124750 125000 22092 22 22070 22092

331250

331

-331

-576280

1910536

1911

34430605

34430

25973925

-502512

-300000

-26769586

-1059320

1066666 1067 404266 405333

21000

9226

9247

250000 250 104750 105000 186516 187 78025 78212

-429567

1910536

1911

35954787

35955

26570192

-502512

-300000

-27199153

-891095

381641 381641 450000 450 224550 225000

5333

2662

2667

15666 16 7223 7239 250000 250 116450 116700

-2556468

1910536

1911

36410120

36410

265666

266

27302718

-502512

-300000

-29755621

-2714316

-3562315

-5698013

1375

346700

4862500

-22257 8902 187000

45801

9999

381641 129153

13752

11986

-16344

5834 32888 37616 -67897 -57650

114000

628520

1646487

-898957

-399939

-50000

470000

27085

86995

18996

665333

430000

500

1058248

498499

159291

98560

37231

373

196522

98933

411000

22092

217000

126250

331

150

1440

45144 55955 198612

35261871

55261871

18144112

196522

2551952

-2714316

-29755621

-3562315

-898957

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the condensed consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Significant estimates include the valuation of deferred tax assets and the associated valuation allowances, the fair value of the Company’s common stock, the valuation of stock-based compensation, the fair value of warrants classified as liabilities, and the grant-date fair value of equity instruments issued as compensation for services. Cash and Cash Equivalents For purposes of the condensed consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market accounts to be cash equivalents. The Company had no cash equivalents at June 30, 2026 and September 30, 2025. The Company maintains its cash on deposits with banks and financial institutions within the United States that at times may exceed federally-insured limits of $250,000. The Company manages this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the credit quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts and believes it is not exposed to any risks on its cash in bank accounts. At June 30, 2026 and September 30, 2025, the Company’s cash balances were not in excess of the federally-insured limits. Deferred Offering Costs Deferred offering costs consist of legal, accounting and other fees and expenses that are directly attributable to a contemplated offering of the Company’s securities. These costs are capitalized and deferred until the offering is completed, at which time they are charged against the gross proceeds of the offering as a reduction of additional paid-in capital. If the offering is abandoned, or is no longer considered probable of being completed, the deferred costs are charged to expense. Fair Value of Financial Instruments and Fair Value Measurements The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"><tbody><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.25in;"></td> <td style="width: 0.25in; text-align: left;">●</td> <td style="text-align: justify;">Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</td> </tr></tbody></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"><tbody><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.25in;"></td> <td style="width: 0.25in; text-align: left;">●</td> <td style="text-align: justify;">Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</td> </tr></tbody></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"><tbody><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.25in;"></td> <td style="width: 0.25in; text-align: left;">●</td> <td style="text-align: justify;">Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.</td> </tr></tbody></table> The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying condensed consolidated financial statements, primarily due to their short-term nature. Certain of the Company’s financial liabilities are measured at fair value on a recurring basis. The Company measures these instruments using an option-pricing model. Because the Company’s common stock is thinly traded, expected volatility is estimated by reference to the historical volatility of comparable publicly traded companies over the expected term of the instrument, and no dividends are assumed. The inputs used in these measurements are unobservable, and the measurements are classified within Level 3 of the fair value hierarchy. Changes in the fair value of these instruments are recognized in other income (expense) in the condensed consolidated statements of operations. The Company recognizes transfers into and out of the levels of the fair value hierarchy as of the beginning of the reporting period in which the transfer occurs. See Note 5 for further disclosures of our financial liabilities measured at fair value on a recurring basis. Extinguishment of Liabilities The Company derecognizes a liability upon it being extinguished. A liability is considered to be extinguished when the obligation resulting in the liability is paid in full with either cash, other financial assets or delivery of goods or services. Further, a liability is considered extinguished if the debtor is legally released from being the primary obligor by the creditor. See Note 3 for liabilities extinguished during the three and nine months ended June 30, 2026 and 2025 that resulted in a gain (loss) on extinguishment. Convertible Notes Payable The Company records convertible notes payable at the amount of proceeds received, net of discounts. Where a convertible note is issued together with a freestanding instrument such as a warrant, the Company allocates the proceeds between the instruments according to the classification of each. Where the freestanding instrument is classified within stockholders’ equity, the proceeds are allocated between the instruments based on their relative fair values in accordance with ASC 470-20-25-2. Where the freestanding instrument is classified as a liability, that instrument is recorded at its full fair value and the residual proceeds are allocated to the note. Original issue discount, and lender legal fees and closing costs withheld from proceeds, together with any amount allocated to a freestanding instrument, are recorded as a discount against the carrying amount of the note. The discount is amortized to interest expense over the contractual term. Where a note becomes due and payable before the end of its stated term, any remaining unamortized discount is recognized in interest expense at that time. The Company evaluates amendments to the terms of its debt instruments under ASC 470-50 to determine whether an amendment is accounted for as a modification or as an extinguishment of the original instrument. Warrants The Company accounts for warrants issued in connection with its financing transactions as either equity-classified or liability-classified instruments based on an assessment of the specific terms of each warrant under ASC 480 and ASC 815-40. The assessment considers whether the instrument is freestanding, whether it meets the definition of a liability under ASC 480, and whether it satisfies the conditions for equity classification under ASC 815-40, including whether the instrument is considered indexed to the Company’s own common stock. The assessment is performed at issuance and at each subsequent reporting date. Equity-classified warrants are recorded within additional paid-in capital at their allocated value on the date of issuance and are not subsequently remeasured. Liability-classified warrants are recorded at fair value on the date of issuance and are remeasured to fair value at each reporting date, with the change in fair value recognized in other income (expense). Upon exercise, a liability-classified warrant is remeasured to fair value as of the exercise date and the resulting amount is reclassified to stockholders’ equity together with any exercise proceeds. The warrants issued in connection with the Company’s convertible notes payable provide that the exercise price of the warrant is conformed to the conversion price under the related note. Under the terms of that note, the conversion price may, in specified circumstances, be adjusted to an amount determined by reference to a market price of the Company’s common stock. Because the exercise price of the warrants is therefore not fixed, the warrants do not satisfy the condition in ASC 815-40-15-7C that the settlement amount equal the difference between the fair value of a fixed number of shares and a fixed monetary amount, and the warrants are classified as liabilities. Embedded Derivatives The Company evaluates the embedded features of its financial instruments to determine whether a feature is required to be separated from its host contract and accounted for separately as a derivative under ASC 815-15-25-1. A feature is separated only if each of the required criteria is met, including the criterion that the feature would, on a freestanding basis, meet the definition of a derivative. For a feature that would be settled in the Company’s own common stock, meeting that definition requires that the shares deliverable upon settlement be readily convertible to cash. The Company’s common stock is quoted on the Over-the-Counter (“OTC”) market and is thinly traded, with no reported trading activity on a substantial portion of trading days. The Company has concluded that the shares deliverable upon conversion of its convertible notes payable are not readily convertible to cash, that the conversion feature accordingly does not meet the definition of a derivative, and that separate accounting for the feature is therefore not required. The Company has not separated any embedded feature from a host contract and has not recognized any derivative liability. Preferred Stock The Company evaluates each series of its preferred stock upon designation and issuance to determine whether the series is classified as a liability, as temporary equity, or as permanent equity, considering the redemption, conversion, voting and settlement provisions of the series in accordance with ASC 480 and ASC 480-10-S99-3A. No series of the Company’s preferred stock is mandatorily redeemable, redeemable at the option of the holder, or redeemable upon an event outside the Company’s control. Accordingly, each series of the Company’s preferred stock is presented within permanent stockholders’ equity. Advertising and Marketing Costs All costs related to advertising and marketing are expensed as incurred. For the three and nine months ended June 30, 2026 and 2025, advertising and marketing costs amounted to $15,281 and $0 and $42,073 and $3,758, respectively. Research and Development The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of plant-based defense technology products. For the three and nine months ended June 30, 2026, and 2025, the Company incurred $205,977 and $271,816 and $320,352 and $390,052 in research and development expenses, respectively. Stock-based Compensation The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all share-based awards, including stock warrants and stock grants, based on estimated grant-date fair values. The Company measures employee and non-employee awards at the date of grant, which generally is the date at which the Company and the non-employee reach a mutual understanding of the key terms and conditions of a share-based payment award. The Company uses the straight-line attribution method to allocate compensation cost to reporting periods over the requisite service period during which the employee or non-employee is required to provide services in exchange for the award. The Company has elected to account for forfeitures of awards as they occur, with previously recognized compensation reversed in the period that the awards are forfeited. Share-based payments to nonemployees are measured at the grant-date fair value of the equity instruments issued rather than at the fair value of the goods or services received. Where an award is fully vested at issuance and is not subject to a service or performance condition, the entire grant-date fair value is recognized on the grant date. Awards classified within stockholders’ equity are not subsequently remeasured. Where an equity instrument issued as compensation is convertible into common stock on terms that vary depending on future events, the Company measures the grant-date fair value of the instrument using a probability-weighted model of the settlement outcomes available under the terms of the instrument, adjusted by a discount for lack of marketability. An award within the scope of ASC 718, together with any conversion feature embedded in it, is excluded from the requirements of ASC 815 under ASC 815-10-15-74(b) for so long as the award remains within the scope of ASC 718, and the conversion feature is not separately evaluated for separation as a derivative. Fair Value of Common Stock The Company’s common stock is quoted on the OTC Market and is thinly traded, with no reported trading activity on a substantial portion of trading days. In determining the fair value of its common stock for the purpose of measuring equity instruments issued and share-based payments, the Company considers the most recent arm’s-length third-party cash sale price of its common stock, the quoted market price, and the volume-weighted average price of executed transactions over a trailing period. Where no trade is reported on a measurement date, the Company does not rely on the last reported sale price and instead determines fair value by reference to a trailing 30-day volume-weighted average price of executed transactions. The Company applies this basis consistently across measurement dates. Reclassification As of September 30, 2025, we reclassified $248 between common stock and additional paid-in capital to reflect the common stock balance as the total shares of common stock issued and outstanding at its $0.001 par value. This reclassification has also been presented on our condensed consolidated statements of changes in stockholders’ deficit as of December 31, 2025 and March 31, 2026. This reclassification had no impact on total stockholders’ deficit or earnings (loss) per share. Per Share Data ASC Topic 260 “Earnings per Share,” requires presentation of both basic and diluted earnings per share (“EPS”) with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. Common stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact. The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td style="font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">Three Months Ended June 30,</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 52%; text-align: left;">Warrants to purchase common stock</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">900,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">100,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">900,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">100,000</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left;">Series A convertible preferred stock</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: left;">Series B convertible preferred stock</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">14,080,240</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">15,580,240</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">14,080,240</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">15,580,240</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left;">Series C convertible preferred stock</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">900,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">900,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: left; padding-bottom: 1.5pt;">Convertible notes</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">20,000</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">20,000</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total potentially dilutive securities</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">15,880,246</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">15,700,246</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">15,880,246</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">15,700,246</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> </tr></tbody></table> The number of shares of common stock issuable upon conversion of the Series C Preferred Stock is not fixed. Each share is convertible into a number of shares of common stock determined by dividing a stated monetary amount by a price per share determined under the Certificate of Designation, subject to a floor price if the Company’s common stock has not been listed on a national exchange at time of conversion. The share amounts presented above for the Series C Preferred Stock reflect the maximum number of shares issuable at the $1.00 floor price. Commitments and Contingencies In the normal course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Segment Reporting The segment reporting structure uses the Company’s management reporting structure as its foundation to reflect how the Company manages the businesses internally and is mainly organized by products. During the nine months ended June 30, 2026 and 2025, the Company was organized into one strategic business unit. Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to make operating decisions, allocate resources and assess performance. The Company’s Chief Executive Officer (“CEO”) is its CODM. The Company’s CODM reviews consolidated operating results, cash balances, liquidity position, financing activities and operating expenses on a consolidated basis when making decisions regarding resource allocation and assessing performance. The Company does not prepare or review discrete financial information for separate product lines, technologies, geographic areas or business activities and therefore has concluded that it operates as a single operating segment. Recent Accounting Standards In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses and about the CODM. The Company adopted ASU 2023-07 effective October 1, 2024, and the adoption did not have a material impact on its condensed consolidated financial statements or disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. Effective October 1, 2025, the Company adopted ASU 2023-09 which did not have an impact on its unaudited condensed consolidated financial condition, results of operations, cash flows or disclosures. In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“DISE”) a new accounting standard to improve the disclosures about an entity’s expenses and address requests from investors for more detailed information about the types of expenses included in commonly presented expense captions. The new standard is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with retrospective application permitted. The Company is evaluating the disclosure requirements related to the new standard and its impact on our consolidated financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.

Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the condensed consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Significant estimates include the valuation of deferred tax assets and the associated valuation allowances, the fair value of the Company’s common stock, the valuation of stock-based compensation, the fair value of warrants classified as liabilities, and the grant-date fair value of equity instruments issued as compensation for services.

250000

Fair Value of Financial Instruments and Fair Value Measurements The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"><tbody><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.25in;"></td> <td style="width: 0.25in; text-align: left;">●</td> <td style="text-align: justify;">Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</td> </tr></tbody></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"><tbody><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.25in;"></td> <td style="width: 0.25in; text-align: left;">●</td> <td style="text-align: justify;">Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</td> </tr></tbody></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"><tbody><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.25in;"></td> <td style="width: 0.25in; text-align: left;">●</td> <td style="text-align: justify;">Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.</td> </tr></tbody></table> The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying condensed consolidated financial statements, primarily due to their short-term nature. Certain of the Company’s financial liabilities are measured at fair value on a recurring basis. The Company measures these instruments using an option-pricing model. Because the Company’s common stock is thinly traded, expected volatility is estimated by reference to the historical volatility of comparable publicly traded companies over the expected term of the instrument, and no dividends are assumed. The inputs used in these measurements are unobservable, and the measurements are classified within Level 3 of the fair value hierarchy. Changes in the fair value of these instruments are recognized in other income (expense) in the condensed consolidated statements of operations. The Company recognizes transfers into and out of the levels of the fair value hierarchy as of the beginning of the reporting period in which the transfer occurs. See Note 5 for further disclosures of our financial liabilities measured at fair value on a recurring basis.

Convertible Notes Payable The Company records convertible notes payable at the amount of proceeds received, net of discounts. Where a convertible note is issued together with a freestanding instrument such as a warrant, the Company allocates the proceeds between the instruments according to the classification of each. Where the freestanding instrument is classified within stockholders’ equity, the proceeds are allocated between the instruments based on their relative fair values in accordance with ASC 470-20-25-2. Where the freestanding instrument is classified as a liability, that instrument is recorded at its full fair value and the residual proceeds are allocated to the note. Original issue discount, and lender legal fees and closing costs withheld from proceeds, together with any amount allocated to a freestanding instrument, are recorded as a discount against the carrying amount of the note. The discount is amortized to interest expense over the contractual term. Where a note becomes due and payable before the end of its stated term, any remaining unamortized discount is recognized in interest expense at that time. The Company evaluates amendments to the terms of its debt instruments under ASC 470-50 to determine whether an amendment is accounted for as a modification or as an extinguishment of the original instrument.

Warrants The Company accounts for warrants issued in connection with its financing transactions as either equity-classified or liability-classified instruments based on an assessment of the specific terms of each warrant under ASC 480 and ASC 815-40. The assessment considers whether the instrument is freestanding, whether it meets the definition of a liability under ASC 480, and whether it satisfies the conditions for equity classification under ASC 815-40, including whether the instrument is considered indexed to the Company’s own common stock. The assessment is performed at issuance and at each subsequent reporting date. Equity-classified warrants are recorded within additional paid-in capital at their allocated value on the date of issuance and are not subsequently remeasured. Liability-classified warrants are recorded at fair value on the date of issuance and are remeasured to fair value at each reporting date, with the change in fair value recognized in other income (expense). Upon exercise, a liability-classified warrant is remeasured to fair value as of the exercise date and the resulting amount is reclassified to stockholders’ equity together with any exercise proceeds. The warrants issued in connection with the Company’s convertible notes payable provide that the exercise price of the warrant is conformed to the conversion price under the related note. Under the terms of that note, the conversion price may, in specified circumstances, be adjusted to an amount determined by reference to a market price of the Company’s common stock. Because the exercise price of the warrants is therefore not fixed, the warrants do not satisfy the condition in ASC 815-40-15-7C that the settlement amount equal the difference between the fair value of a fixed number of shares and a fixed monetary amount, and the warrants are classified as liabilities.

15281

42073

3758

205977

271816

320352

390052

248

0.001

The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td style="font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">Three Months Ended June 30,</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 52%; text-align: left;">Warrants to purchase common stock</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">900,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">100,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">900,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">100,000</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left;">Series A convertible preferred stock</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: left;">Series B convertible preferred stock</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">14,080,240</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">15,580,240</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">14,080,240</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">15,580,240</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left;">Series C convertible preferred stock</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">900,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">900,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: left; padding-bottom: 1.5pt;">Convertible notes</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">20,000</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">20,000</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total potentially dilutive securities</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">15,880,246</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">15,700,246</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">15,880,246</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">15,700,246</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> </tr></tbody></table>

900000

100000

900000

100000

14080240

15580240

14080240

15580240

900000

20000

15880246

15700246

15880246

15700246

NOTE 3 – EXTINGUISHMENT OF LIABILITIES During the nine months ended June 30, 2026, the Company settled $25,400 of accounts payable with cash payments of $9,500 and recognized a gain of $15,900. Further, the Company issued 186,516 shares of its common stock with an estimated fair value of $78,212 based on recent sales of common stock for the settlement of accounts payable totaling $55,955 resulting in a loss on the settlement of the accounts balance of $22,257 (see also Note 8) which is included in the net loss on settlement of accounts payable on the condensed unaudited consolidated statement of operations. During the nine months ended June 30, 2025, the Company issued an aggregate of 120,000 shares of common stock with an estimated fair value of $30,000 based on recent sales of common stock for the settlement of $43,902 of outstanding accounts payable balances. The settlement resulted in a net gain of approximately $13,902, which is included in net gain on settlement of liabilities on the unaudited condensed consolidated statements of operations. Further, the Company executed a release and settlement agreement with its former CEO for amounts owed to the former CEO totaling $50,000. Pursuant to the release and settlement agreement, the Company agreed to pay $55,000 for the settlement of all amounts outstanding with this individual and recognized a loss of $5,000 which has been netted with the gain on settlement of accounts payable, net, on the condensed unaudited consolidated statements of operations.

25400

9500 15900 186516 78212 55955 22257 120000 30000

43902

13902

50000

55000 5000

NOTE 4 – NOTES PAYABLE Evergreen Convertible Notes Payable and Warrant Liabilities Effective April 16, 2026, the Company entered into a securities purchase agreement (the “SPA”) with Evergreen Capital Management LLC (“Evergreen”), pursuant to which the Company sold, and Evergreen purchased, (i) a convertible promissory note in the aggregate principal amount of up to $800,000 (the “Note”), and (ii) warrants to purchase up to 600,000 shares of Company common stock (the “Warrants”), for an aggregate purchase price of up to $666,668 (the “Purchase Price”). The Purchase Price was to be paid in four tranches of $166,667 (each, a “Tranche”), with the first Tranche paid at the initial closing of the transaction, and the remaining three Tranches paid to the Company upon (i) the Company’s filing of a registration statement on Form S-1 registering for resale shares of Company common stock issuable upon conversion of the Note, and (ii) receiving comments from the SEC on that registration statement. Evergreen shall retain $10,000 from each Tranche to cover its legal fees and closing costs. The first Tranche was funded on April 16, 2026, and on that date, the Note and Warrants were issued to Evergreen. On June 17, 2026 (the “Effective Date”), the Company and Evergreen entered into a side letter agreement (the “Letter Agreement”), pursuant to which, among other things: (i) Evergreen’s registration rights, including its piggyback registration rights, were deleted from the SPA; (ii) the number of Warrants to be issued for the four tranches was increased from 600,000 to up to 1,200,000; (iii) Evergreen accelerated the funding of the second and third Tranches such that, on the Effective Date, the Company received net proceeds of $333,334; and (iv) the fourth Tranche in the amount of $166,667 (the “Fourth Tranche”) may be funded at the option of Evergreen, provided that Evergreen’s option to fund the Fourth Tranche will expire upon the maturity date of the Note. At June 30, 2026, the Company received aggregate net proceeds from the first three Tranches of $470,000, after an original issue discount (“OID”) of $100,000 and Evergreen’s legal fees of $30,000 from the funding of the three tranches and Evergreen received Warrants to purchase up to an aggregate of 900,000 shares of the Company’s common stock. The issuance of the notes pursuant to the April 16 and June 17 Tranches are collectively referred to as the “Notes.” The Notes mature upon the earlier of (i) 9 months following the issue date set forth in the respective Note, or (ii) the listing of the Company’s common stock on a national securities exchange (an “Exchange Listing”). The Note accrues interest at 10% per annum and is convertible into shares of the Company’s common stock at $1.00 per share, or 80% of the lowest volume-weighted average price during the five trading days preceding conversion upon the occurrence of any event of default; provided, however, that the holder may not convert the Note to the extent that such conversion would result in the holder’s beneficial ownership of the Company’s common stock being in excess of 4.99% of the Company’s issued and outstanding common stock. At June 30, 2026, no event of default had occurred and the default conversion price was not in effect. Further, the conversion price is subject to adjustment upon a reverse stock split or other capitalization that results in a reduction of the number of outstanding shares of common stock. The conversion price and any other price-based measure used to determine the number of shares of common stock issuable upon conversion shall be proportionately and equitably adjusted such that, following such reverse stock split or recapitalization, the holder shall be entitled to receive upon conversion the number of shares of common stock that the holder would have been entitled to receive had such conversion occurred immediately prior to such reverse stock split or recapitalization, with such adjustment resulting in a conversion price equal to the lowest volume weighted-average price of the common stock during the ten consecutive trading days immediately following the effectiveness of such reverse stock split. The conversion price is also subject to adjustment for any issuances or sales of common stock or common stock equivalents at a price per share that is lower than the applicable conversion price. The Warrants have a five-year term, are exercisable on a cashless basis, and have an initial exercise price of $1.00, subject to adjustment so that the exercise price under the Warrants equals the applicable conversion price under the Notes. Pursuant to the Warrant, if at any time after the six-month anniversary of the issuance date, the Market Price (as defined in the Warrant) of one share of common stock is greater than the exercise price and the shares of common stock issuable upon exercise of the Warrants are not registered pursuant to an effective registration statement, Evergreen may exercise the Warrants on a cashless basis. The exercise price of the Warrants issued in connection with the Notes are deemed conformed to the conversion price of the Notes and are therefore subject to the same default adjustment. Because the exercise price may be reset to a variable amount determined by reference to the market price of the common stock, the Warrants are not considered indexed to the Company’s own stock under ASC 815-40-15-7C which requires the settlement amount equal the difference between the fair value of a fixed number of shares and a fixed monetary amount. Therefore, the Warrants are classified as liabilities measured at fair value on a recurring basis, with changes in fair value recognized in earnings. In accordance with ASC 470-20-25-2, we allocated the proceeds received between the Notes and Warrants using the with-and-without method, since the Warrants are classified as a liability. Therefore, $198,612 of the total proceeds were allocated to the Warrants based on the Warrants’ fair value at issuance and have been presented as a discount against the Notes to be amortized into interest expense over the nine-month term of the Notes and an increase to warrant liabilities. The fair value allocation was based on the estimated fair value of the Warrants at each issuance date of April 16 and June 17, 2026 determined using a Black-Scholes pricing model and the following key assumptions: expected term of five years (based on the contractual term of the Warrants), volatility of approximately 93% (based on peer companies over the expected term), risk free rates of 3.91% and 4.27%, respectively, (based on the U.S. Treasury yield curve in effect at the time of grant for the period for the expected term), underlying common stock of $0.49 and $0.32 (30-day volume weighted average price on date of issuance), respectively, per share and dividend rate of 0.00%. At June 30, 2026, we remeasured the estimated fair value of the warrant liabilities using the Black-Scholes pricing model and the following key assumptions: expected term of approximately five years (based on the contractual term of the Warrants), volatility of approximately 93% (based on peer companies over the expected term), risk free rate of 4.14% (based on the U.S. Treasury yield curve in effect at the time of grant for the period for the expected term), underlying common stock of $0.4079 (30-day volume weighted average price). This resulted in an unrealized loss of $13,752 for the change in the warrant liabilities fair value. See Note 5 for further fair value measurement related disclosures. During the three and nine months ended June 30, 2026, we recognized interest expense on the Notes of $5,834. During the three and nine months ended June 30, 2026, we recognized amortization expense of $45,801 related to the debt discounts for the OID, lender legal fees and warrant liabilities which has been included within interest expense on the condensed consolidated statements of operations. At June 30, 2026, the unamortized debt discount is $282,812. For the three and nine months ended June 30, 2025, amortization of debt discount related to the convertible note payable amounted to $3,333 and $9,999, respectively, which has been included in interest expense on the accompanying condensed consolidated statements of operations. The convertible note payable and unamortized debt discount at June 30, 2026 and September 30, 2025 was as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">June 30, 2026</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">September 30, 2025</td> <td style="padding-bottom: 1.5pt;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 76%; text-align: justify;">Principal amount</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">600,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">20,000</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: justify; padding-bottom: 1.5pt;">Less: unamortized debt discount</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">282,811</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: justify; padding-bottom: 2.5pt;">Convertible note payable, net</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; text-align: right;">317,189</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; text-align: right;">20,000</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> </tr></tbody></table> 2024 Convertible Note Payable On September 9, 2024, the Company and an investor entered into a convertible promissory note agreement providing for the issuance of a note in the principal amount of $20,000. The note was due on September 9, 2025. The principal amount was convertible into shares of common stock of the Company at a conversion price of $1.00 per share. In addition, the Company issued the investor a stock purchase warrant to acquire 40,000 shares of common stock of the Company at a per share price of $0.01. The warrants were immediately exercisable. In accordance with ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds so allocated to the warrants are accounted for as additional paid-in capital. The remainder of the proceeds are allocated to the debt instrument portion of the transaction. The fair value of the warrants issued to the investor was $40,000. Therefore, the Company recorded debt discount of $13,333 related to the relative fair value of the warrants issued to the investor, which was amortized over the term of the note. In October 2025, the convertible note and all accrued interest of $22,092 was converted into 22,092 shares of common stock (see Note 7) at the stated conversion price of $1.00. SBA Loan On April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program (“PPP”) in the principal amount of $48,750. The note bears interest at a variable rate of approximately 1% and matured in April 2022. The Company applied for forgiveness of the loan. No determination has been received and the loan remains outstanding. Financed Payable During the three months ended June 30, 2026, the Company entered into a financing agreement to finance $45,144 of insurance premiums due on various policies. The financed amount is due in fixed monthly payments of $4,807 for a period of ten months and bears interest at 13.9%. The balance of $18,059 remaining on this financing liability has been presented within current liabilities on the accompanying condensed consolidated balance sheets as of June 30, 2026.

800000

600000

666668

166667

10000

600000

1200000

333334

166667

470000

100000

30000

900000

0.10

0.80

0.0499

198612

0.93

0.0391

0.0427

0.49

0.32

P30D

0.93

0.0414

0.4079

P30D

13752

5834

45801

282812

3333

9999

The convertible note payable and unamortized debt discount at June 30, 2026 and September 30, 2025 was as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">June 30, 2026</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">September 30, 2025</td> <td style="padding-bottom: 1.5pt;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 76%; text-align: justify;">Principal amount</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">600,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">20,000</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: justify; padding-bottom: 1.5pt;">Less: unamortized debt discount</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">282,811</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: justify; padding-bottom: 2.5pt;">Convertible note payable, net</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; text-align: right;">317,189</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; text-align: right;">20,000</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> </tr></tbody></table>

600000

20000

282811

317189

20000

40000

0.01

40000

13333

22092

48750

0.01

45144

4807

0.139

18059

The following table sets forth the Company’s financial liabilities measured at fair value on a recurring basis, by level within the fair value hierarchy, at June 30, 2026 and September 30, 2025: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid;">Warrant liabilities</td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">June 30, 2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">September 30, 2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: justify;">Level 1</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: justify;">Level 2</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt;">Level 3</td> <td style="width: 1%; padding-bottom: 1.5pt;"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;">212,364</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"> </td> <td style="width: 1%; padding-bottom: 1.5pt;"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;">212,364</td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"> —</td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"> </td> </tr></tbody></table>

212364

The following table presents a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the nine months ended June 30, 2026: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid;">Level 3 warrant liability</td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">Amount</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: justify;">Balance at September 30, 2025</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="width: 88%; text-align: justify;">Warrants issued</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">198,612</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: justify; padding-bottom: 1.5pt;">Change in fair value recognized in earnings</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">13,752</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt;">Balance at June 30, 2026</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;">212,364</td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: left;"> </td> </tr></tbody></table>

198612

13752

212364

The fair value of the warrant liabilities are estimated using the Black-Scholes option-pricing model. The significant unobservable inputs used in the measurement of the warrant liabilities at June 30, 2026 were as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid;">Significant unobservable input</td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">June 30, 2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="width: 88%; text-align: justify; padding-left: 0in;">Expected volatility</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">93.41</td> <td style="width: 1%; text-align: left;">%</td> </tr><tr style="vertical-align: bottom; background-color: White;"><td style="text-align: justify; padding-left: 0in;">Underlying common stock price</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.4079</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify; padding-left: 0in;">Remaining contractual term</td> <td> </td> <td style="text-align: left;"> </td> <td style="white-space: nowrap; text-align: right;">4.79 – 4.96 years</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"><td style="text-align: justify; padding-left: 0in;">Risk-free interest rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4.14</td> <td style="text-align: left;">%</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"><td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0in;">Expected dividend yield</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt; text-align: right;">0.00</td> <td style="padding-bottom: 1.5pt; text-align: left;">%</td> </tr></tbody> </table>

93.41

0.4079

4.79

4.96

4.14

300000

1200000 300000 1

0.001

300000

300000 1 0.30 0.25 P30D

381641

0.30 0.70

P30D 0.489 0.3242 0.25

NOTE 7 – STOCKHOLDERS’ DEFICIT Preferred Stock The authorized preferred stock of the Company consists of 20,000,000 shares with a $0.001 par value. Series A Preferred Stock On August 10, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series A Preferred Stock (“Series A”). The designation authorized 10 shares of Series A. Each share of Series A entitles the holder to 10,000,000 votes on all matters submitted to a vote of the stockholders of the Company. When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to participate in such dividend or distribution. Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled to receive out of the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of the Company). As of both June 30, 2026 and September 30, 2025, there were 6 shares of Series A issued and outstanding. Series B Preferred Stock On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock (“Series B”). The designation authorized 2,500,000 shares of Series B. Each share of Series B entitles the holder to 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. On September 28, 2023, our former Chief Executive Officer and the LASB Family Trust returned to the Company for cancellation of 502,512 shares of Series B; however, the shares have not been canceled and are being held in treasury stock. During the nine months ended June 30, 2026, PJ Advisory Group converted their Series B into 1,500,000 shares of common stock. At June 30, 2026 and September 30, 2025, there were 1,910,536 and 2,060,536 Series B issued and 1,408,024 and 1,558,024 Series B outstanding, respectively. Series C Preferred Stock On May 5, 2026, the Company filed a Certificate of Designation with the State of Nevada to designate its Series C Preferred Stock. The designation authorized four shares of preferred stock as Series C. Each share of Series C has a nominal liquidation preference equal to par value ($0.001 per share), does not have preferential voting or dividend rights (with each holder of a share of Series C having one vote per share, and the right to participate equally with common stockholders), but will have preferential conversion rights. Each share of Series C is convertible, at the option of the holder, into a number of shares of common stock at the following conversion rates: (i) if the common stock has been listed for trading on The Nasdaq Capital Market, the NYSE American, or another equivalent national securities exchange by April 14, 2027, the Series C will convert at a rate of $300,000 divided by the official closing price of the Company’s common stock reported by The Nasdaq Capital Market, the NYSE American, or other exchange, or (ii) if the Company’s common stock is not listed on a national securities exchange within one year of the date of the Advisory Agreement, the Series C will be convertible into common stock at $300,000 per tranche based on the five-day average closing price of the OTC Market (if the common stock has not been listed with a national securities exchange), but in no event at less than $1.00 per share. During the three and nine months ended June 30, 2026, 3 shares of Series C were issued to the Consultant pursuant to the Advisory Agreement (see Note 6). Common Stock The Company is authorized to issue up to 300,000,000 shares of common stock with a $0.001 par value. All common stock shares are non-assessable and have one vote per share. During the nine months ended June 30, 2026 and 2025, the Company issued the following shares of common stock: Common stock for conversion of Series B During the nine months ended June 30, 2026, the Company issued 1,500,000 shares of its common stock for the conversion of 150,000 shares of Series B. Common stock issued for cash During the nine months ended June 30, 2026, the Company issued 1,586,666 shares of its common stock and received cash proceeds of $665,333, which includes the exercise of a 533,333 pre-funded warrant with an exercise price of $0.01. The common stock shares were sold for an average price per share of $0.42 per share. During the nine months ended June 30, 2025, the Company sold an aggregate of 1,720,000 shares of its common stock at a price of $0.25 per share to investors and received gross proceeds of $430,000. Common stock for warrant exercises During the nine months ended June 30, 2026, the Company issued 1,440,000 shares of its common stock upon the cashless exercise of warrants. During the nine months ended June 30, 2025, the Company issued 500,000 shares of its common stock upon the exercise of warrants with an exercise price of $0.001 per share and received gross proceeds of $500. Common stock for services During the nine months ended June 30, 2026, the Company issued 251,333 shares of common stock and has 15,666 shares of its common stock to be issued for $129,153 of consulting services pursuant to consulting agreements which have been reflected within professional fees on the accompanying unaudited condensed consolidated statements of operations. Common stock for accrued services During the nine months ended June 30, 2026, the Company issued 505,000 shares of its common stock for $126,250 of consulting services provided that were accrued for as of September 30, 2025. Common stock for conversion of accrued compensation During the nine months ended June 30, 2026, the Company issued 574,000 shares of its common stock for the conversion of $411,000 of accrued compensation owed to its CEO and a director and advisor of the Company. During the nine months ended June 30, 2025, the Company issued 1,300,000 shares of its common stock upon the conversion of $125,000 of accrued compensation outstanding with its CEO and $200,000 of accrued bonuses with its two scientific advisor employees, totaling $325,000. Common stock for compensation During the nine months ended June 30, 2026, the Company issued its current CEO 500,000 shares of common stock pursuant to an employment agreement which provides the CEO with 250,000 shares of common stock each calendar quarter as compensation (see Note 9). During the nine months ended June 30, 2026, the Company recognized stock-based compensation expense on the fully vested and issued shares of $230,000 based on the current price being paid for shares of common stock. During the three months ended June 30, 2026, the Company has reflected 250,000 shares of stock to be issued to the CEO and recognized stock-based compensation of $116,700 based on a 90-day volume weighted average share price per the OTC Market due to no sales of stock for cash occurring during the three months ended June 30, 2026. During the nine months ended June 30, 2025, the Company issued an aggregate of 5,375,000 shares of its common stock to its chief executive officer for services rendered during the nine months ended June 30, 2025. These shares were valued at an aggregate of $5,000,000 using the most recent common stock sales on the date of grant. The Company recorded stock-based compensation expense of $62,500 and $4,862,500 for the three and nine months ended June 30, 2025, respectively, which has been included in compensation and related expenses on the unaudited consolidated statements of operations, and reduced accrued compensation by $137,500 that had been accrued as of September 30, 2024 related to shares of common stock that had vested for services but were not issued. Common stock for conversion of note payable and accrued interest During the nine months ended June 30, 2026, the Company issued 22,092 shares of its common stock for the conversion of a note payable and accrued interest totaling $22,092 (see Note 4). During the nine months ended June 30, 2025, Brent Lilienthal converted his note payable with a principal amount of $217,000 into 120,000 shares of common stock with an estimated fair value of $30,000 based on recent sales of common stock. The conversion resulted in a gain of approximately $187,000 as presented on the unaudited condensed consolidated statements of operations. During the nine months ended June 30, 2025, the Company issued 310,000 shares of common stock for the conversion of $220,000 of principal and accrued interest that occurred during the fiscal year ended September 30, 2024 for which the shares had not previously been issued. Cancellation of common stock due to legal settlement During the nine months ended June 30, 2026, pursuant to a legal settlement (see Note 9), the Company cancelled 331,250 shares of its common stock. Common stock for settlement of accounts payable On March 11, 2026, the Company issued 186,516 shares of its common stock with an estimated fair value of $78,212 based on recent sales of common stock for the settlement of accounts payable totaling $55,955. During the nine months ended June 30, 2026, the Company recognized a loss on the settlement of the accounts balance of $22,257 which is included in net gain (loss) on settlement of accounts payable on the condensed consolidated statements of operations. During the nine months ended June 30, 2025, the Company issued an aggregate of 120,000 shares of common stock with an estimated fair value of $30,000 based on recent sales of common stock for the settlement of $43,902 of outstanding accounts payable balances. The settlement resulted in a net gain of approximately $13,902, which is included in net gain on settlement of liabilities on the unaudited condensed consolidated statements of operations. Warrants Common stock warrants activity for the three and nine months ended June 30, 2026 was as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">Number of Warrants</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">Weighted Average Contractual Term</td> <td style="padding-bottom: 1.5pt;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 64%; text-align: left;">Outstanding and exercisable at October 1, 2025</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">3,150,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">0.001</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">0.57</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="padding-bottom: 1.5pt;">Exercised</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">(1,440,000</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">0.001</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: left;">Outstanding and exercisable at December 31, 2025</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,710,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.001</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.32</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td>Issued</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">900,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.00</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="padding-bottom: 1.5pt;">Expired</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">(1,710,000</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">0.001</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left; padding-bottom: 2.5pt;">Outstanding and exercisable at June 30, 2026</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">900,000</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; text-align: right;">1.00</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">4.90</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> </tr></tbody></table> No cash proceeds were received upon the warrants being exercised.

20000000

0.001

10 10000000

Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock.

2500000

Each share of Series B entitles the holder to 10 votes on all matters submitted to a vote of the stockholders of the Company.

Each share of Series B is convertible into 10 shares of common stock of the Company.

502512

1500000

1910536

2060536

1408024

1558024

0.001

one

300000

3 3

300000000

0.001

one

1500000

150000

1586666

665333

533333

0.01

0.42

1720000

0.25

430000

1440000

500000

0.001

500

251333

15666

129153

505000

126250

574000 411000

1300000

125000

200000

325000 325000 500000 250000

230000

250000 116700 P90D

5375000

5000000

62500

4862500

137500

22092 22092

217000

120000

30000

187000

310000

220000

331250

186516

78212

55955 22257 120000

30000

43902 13902

Common stock warrants activity for the three and nine months ended June 30, 2026 was as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">Number of Warrants</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;">Weighted Average Contractual Term</td> <td style="padding-bottom: 1.5pt;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 64%; text-align: left;">Outstanding and exercisable at October 1, 2025</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">3,150,000</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">0.001</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 9%; text-align: right;">0.57</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="padding-bottom: 1.5pt;">Exercised</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">(1,440,000</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">0.001</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: left;">Outstanding and exercisable at December 31, 2025</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,710,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.001</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.32</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td>Issued</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">900,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.00</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="padding-bottom: 1.5pt;">Expired</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">(1,710,000</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">0.001</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">—</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left; padding-bottom: 2.5pt;">Outstanding and exercisable at June 30, 2026</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">900,000</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; text-align: right;">1.00</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;"> </td> <td style="border-bottom: Black 4pt double; text-align: right;">4.90</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> </tr></tbody></table>

3150000

0.001

P0Y6M25D

1440000

0.001

1710000

0.001

P0Y3M25D

900000 1

1710000

0.001

P4Y10M24D

300000

350000

0.30

500000

250000

200488

324238

17500

10000

234000

362500

0.08

6250

7750

11000

0.06

484392

781392

38904

1646487

1567919

525388

330000 1646487

1650000

At June 30, 2026, the liabilities resulting from the Policy are comprised of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid;">Amount</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 88%; text-align: left;">Accrued compensation, CEO</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">477,252</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left;">Accrued compensation, Director Yates</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">94,316</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="text-align: left;">Accrued compensation, Director Jaynes</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">67,540</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left;">Accrued taxes</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">803,045</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="padding-bottom: 1.5pt; text-align: left;">Accrued penalties and interest</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">204,334</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="padding-left: 0.125in; padding-bottom: 4pt; text-align: left;">Total tax reimbursement policy liabilities</td> <td style="padding-bottom: 4pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; text-align: right;">1,646,487</td> <td style="padding-bottom: 4pt; text-align: left;"> </td> </tr></tbody></table>

477252 94316 67540

803045

204334 1646487 During the three and nine months ended June 30, 2026, expenses associated with the Policy have been classified as follows, within the condensed statements of operations: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; text-align: center;"> </td> <td style="padding-bottom: 1.5pt; text-align: center;"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;">Three and Nine Months Ended June 30, 2026</td> <td style="padding-bottom: 1.5pt; text-align: center;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 88%; text-align: left;">Compensation and related benefits</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">1,201,729</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left;">Research and development expenses</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">161,856</td> <td style="text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="padding-bottom: 1.5pt; text-align: left;">Other general and administrative expenses</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">204,334</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="padding-left: 0.125in; padding-bottom: 4pt; text-align: left;">Total tax reimbursement policy expense</td> <td style="padding-bottom: 4pt;"> </td> <td style="border-bottom: Black 4pt double; text-align: left;">$</td> <td style="border-bottom: Black 4pt double; text-align: right;">1,567,919</td> <td style="padding-bottom: 4pt; text-align: left;"> </td> </tr></tbody></table>

1201729

161856

204334

1567919

0.08

0 72843 84137 84137

0.08

10214

5410

82217

49405

92431

54815

9708

37616

12305

31403

331250

50000

5000

9167

100000 25000 100000 25000 100000 25000 10000000 100000 25000

50000

5000

8333

100000 25000 100000 25000 100000 25000 10000000 100000 25000

300000

350000

0.30 500000 250000 5000000 P30D

6250

14000

7750

0.06

575000

425000

150000

7843555

1-for-2

1-for-25

false false false false